Article Details
Retrieved on: 2025-08-08 22:41:43
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... immune system modulators. aTyr's lead drug, efzofitimod, just completed enrollment in its phase 3 EFZO-FIT trial for pulmonary sarcoidosis, with ...
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here